If you suffer from either colitis or Crohn’s disease and your doctor wants to tell you about Entyvio drug, as ulcerative colitis treatment option, think carefully before you give the go ahead. There are some things you should know first… and they’re things that your doctor may not even know about.
Back in December, the American (FDA) announced that it was very alarmed about the dangers of Entyvio used as ulcerative colitis treatment. So much so that it wondered if its risks could possibly outweigh the benefits.The FDA considered restricting the use of Entyvio as ulcerative colitis treatment and there was even talk about a black box warning… trial data showed that the drug didn’t succeed in putting patients in remission after 6 weeks of treatment and it carries the risk of “liver injury that may lead to death” or require a liver transplant, as well as allergic reactions and infections.
At the end of May 2014 the FDA made a 180 degree turn-around and approved this risky drug as ulcerative colitis treatment for Crohn’s disease.The big worry is that Entyvio which is used as ulcerative colitis treatment works just like Tysabri it triggered a rare virus that attacks the brain.This deadly viral brain infection is called progressive multifocal leukoencephlopathy (PML) and back in 2005 the FDA put all Tysabri drug trials on hold when several patients came down with PML.